PEGylated anti-MUC1 aptamer-doxorubicin complex for targeted drug delivery to MCF7 breast cancer cells

Lihan Tan; Koon Gee Neoh; En Tang Kang; Woo Seok Choe; Xiaodi Su

doi:10.1002/mabi.201100173

PEGylated anti-MUC1 aptamer-doxorubicin complex for targeted drug delivery to MCF7 breast cancer cells

Lihan Tan, Koon Gee Neoh, En Tang Kang, Woo Seok Choe, Xiaodi Su

Department of Chemical Engineering

Research output: Contribution to journal › Article › peer-review

81 Scopus citations

Abstract

Targeted drug delivery is especially important in cancer treatment as many anti-cancer drugs are non-specific and highly toxic to both cancer and normal cells. The targeted drug delivery of DOX to the MUC1-expressing breast cancer cell line (MCF7) was obtained using APT as a carrier. Modification of the APT-DOX complex by PEG increases the survivability of the macrophage control (RAW 264.7) by about six-fold as compared to free DOX treatment without significantly affecting the cytotoxicity toward the target cell line. Thus, PEG-APT-DOX is potentially a new therapeutic agent for targeted drug delivery to MUC1-expressing cell lines.

Original language	English
Pages (from-to)	1331-1335
Number of pages	5
Journal	Macromolecular Bioscience
Volume	11
Issue number	10
DOIs	https://doi.org/10.1002/mabi.201100173
State	Published - 10 Oct 2011

Keywords

Aptamers
Biological applications of polymers
Breast cancer
Doxorubicin
Drug delivery systems

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/mabi.201100173

Cite this

@article{86b22385543f405088ec99c17ae87fea,

title = "PEGylated anti-MUC1 aptamer-doxorubicin complex for targeted drug delivery to MCF7 breast cancer cells",

abstract = "Targeted drug delivery is especially important in cancer treatment as many anti-cancer drugs are non-specific and highly toxic to both cancer and normal cells. The targeted drug delivery of DOX to the MUC1-expressing breast cancer cell line (MCF7) was obtained using APT as a carrier. Modification of the APT-DOX complex by PEG increases the survivability of the macrophage control (RAW 264.7) by about six-fold as compared to free DOX treatment without significantly affecting the cytotoxicity toward the target cell line. Thus, PEG-APT-DOX is potentially a new therapeutic agent for targeted drug delivery to MUC1-expressing cell lines.",

keywords = "Aptamers, Biological applications of polymers, Breast cancer, Doxorubicin, Drug delivery systems",

author = "Lihan Tan and Neoh, \{Koon Gee\} and Kang, \{En Tang\} and Choe, \{Woo Seok\} and Xiaodi Su",

year = "2011",

month = oct,

day = "10",

doi = "10.1002/mabi.201100173",

language = "English",

volume = "11",

pages = "1331--1335",

journal = "Macromolecular Bioscience",

issn = "1616-5187",

publisher = "Wiley-VCH Verlag",

number = "10",

}

TY - JOUR

T1 - PEGylated anti-MUC1 aptamer-doxorubicin complex for targeted drug delivery to MCF7 breast cancer cells

AU - Tan, Lihan

AU - Neoh, Koon Gee

AU - Kang, En Tang

AU - Choe, Woo Seok

AU - Su, Xiaodi

PY - 2011/10/10

Y1 - 2011/10/10

N2 - Targeted drug delivery is especially important in cancer treatment as many anti-cancer drugs are non-specific and highly toxic to both cancer and normal cells. The targeted drug delivery of DOX to the MUC1-expressing breast cancer cell line (MCF7) was obtained using APT as a carrier. Modification of the APT-DOX complex by PEG increases the survivability of the macrophage control (RAW 264.7) by about six-fold as compared to free DOX treatment without significantly affecting the cytotoxicity toward the target cell line. Thus, PEG-APT-DOX is potentially a new therapeutic agent for targeted drug delivery to MUC1-expressing cell lines.

AB - Targeted drug delivery is especially important in cancer treatment as many anti-cancer drugs are non-specific and highly toxic to both cancer and normal cells. The targeted drug delivery of DOX to the MUC1-expressing breast cancer cell line (MCF7) was obtained using APT as a carrier. Modification of the APT-DOX complex by PEG increases the survivability of the macrophage control (RAW 264.7) by about six-fold as compared to free DOX treatment without significantly affecting the cytotoxicity toward the target cell line. Thus, PEG-APT-DOX is potentially a new therapeutic agent for targeted drug delivery to MUC1-expressing cell lines.

KW - Aptamers

KW - Biological applications of polymers

KW - Breast cancer

KW - Doxorubicin

KW - Drug delivery systems

UR - https://www.scopus.com/pages/publications/80053903275

U2 - 10.1002/mabi.201100173

DO - 10.1002/mabi.201100173

M3 - Article

C2 - 21818856

AN - SCOPUS:80053903275

SN - 1616-5187

VL - 11

SP - 1331

EP - 1335

JO - Macromolecular Bioscience

JF - Macromolecular Bioscience

IS - 10

ER -

PEGylated anti-MUC1 aptamer-doxorubicin complex for targeted drug delivery to MCF7 breast cancer cells

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this